Overview

Risk Reduction in Coronary Heart Disease

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Study hypothesis: Multifactorial risk reduction in coronary heart disease can reduce the risk of new coronary heart disease and death
Phase:
N/A
Details
Lead Sponsor:
Sorlandet Hospital HF
Collaborator:
Oslo University Hospital
Treatments:
Adrenergic beta-Antagonists
Diuretics
Ezetimibe
Glimepiride
Insulin
Metformin
Vaccines